Palmitate impairs angiogenesis via suppression of cathepsin activity

JIN ZHANG, YING SHAN, YONG LI, XINPING LUO and HAIMING SHI

Department of Cardiology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China

Received January 12, 2016; Accepted January 17, 2017

DOI: 10.3892/mmr.2017.6463

Abstract. Angiogenesis requires the interaction of multiple variable factors to promote endothelial cell adhesion, migration and survival. Palmitate, a free fatty acid, exhibits an anti-angiogenic effect via interference with endothelial cell function, whereas cysteine proteases are important in protein turnover and are termed positive modulators of neovascularization. However, the association between these two factors regarding the regulation of human endothelial cell function remains to be elucidated. By using cell counting kit-8, the Transwell method and an annexin V-fluorescein isothiocyanate/propidium iodide apoptosis detection kit, the present study reported that high levels of palmitate result in a significant decrease in endothelial cell proliferation and invasion, and induced cell apoptosis; cathepsin L and S inhibitors may suppress palmitate-induced apoptosis. Conversely, the results of the cathepsin L and S activity assay and reverse-transcription-quantitative polymerase chain reaction indicated that palmitate inhibited cathepsin-induced endothelial cell invasion, partially via suppressing the expression and activity of cathepsin L and S. The findings of the present study suggested that the potent anti-angiogenic properties of palmitate may be mediated by cysteine proteases.

Introduction

Angiogenesis is a complex multi-step process that occurs in response to ischemic stimuli. These steps include degradation of the basement membrane, proliferation, apoptosis and invasion of endothelial cells, tube formation, and anastomosis (1,2). Various proteases including the family of matrix metalloproteinases (MMPs), and cysteine and serine proteases contribute to the complex processes of new vessel formation and remodeling. Urbich et al (3) demonstrated that cysteine protease cathepsin L-deficient mice presented impaired wound recovery, indicating an important role for cathepsin L in neovascularization. Furthermore, the study validated the ability of cathepsin L to induce angiogenesis, as transferred cathepsin L-deficient progenitor cells did not migrate to ischemic areas or augment vasculogenesis. Conversely, forced expression of cathepsin L in mature endothelial cells markedly enhanced cell invasion. Furthermore, Shi et al (4) demonstrated that cathepsin S was required for microvessel formation. Cysteine proteases have previously been demonstrated to be important in apoptosis and cell survival, separate from their role in proteolysis of extracellular matrix in vascular remodeling (5-7); however, the underlying mechanism of this process remains to be fully elucidated.

Angiogenesis is associated with atherosclerosis, and numerous risk factors of atherosclerosis, including diabetes and insulin resistance, are accompanied by high levels of free fatty acids (FFA) (8,9). However, the specific role of FFAs and their association with angiogenesis remains to be elucidated. FFAs have been demonstrated to exert effects on endothelial cells via enhancing reactive oxygen species levels or impairing nitric oxide production (10); therefore, increased levels of FFA will inhibit angiogenesis. Palmitate, which is the most frequently occurring form of saturated FFA present in human serum, contributes to lipotoxicity (11). In addition to the aforementioned characteristics, palmitate has been detected to induce apoptosis in a variety of tissues (10,12,13) and decrease cardiolipid synthesis, resulting in the release of cytochrome c (14).

Cathepsin L and S have therefore been confirmed to be important in endothelial cell angiogenesis; however, it remains to be elucidated as to whether FFA levels may influence cathepsin-mediated angiogenesis. The present study examined the proliferation, apoptosis and invasion of human umbilical vein endothelial cells (HUVECs) following exposure to palmitate in the presence or absence of selective cathepsin inhibitors, and observed that palmitate impaired cathepsin protein expression levels and activity.

Materials and methods

Cell culture and incubation with fatty acids. HUVECs were purchased from the American Type Culture Collection (Manassas, VA, USA; PCS-100-010) and cultured in M199 medium (HyClone; GE Healthcare Life Sciences,
Logan, UT, USA) supplemented with 20% fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences) at 37°C in an atmosphere containing under 5% CO₂. Cells were passaged every 2-3 days once they reached maximum confluence. Cells were incubated in M199/10% FBS medium supplemented with 0.05, 0.1, 0.2, 0.4 or 0.6 mM palmitate (Sigma-Aldrich; Merck KGAa, Darmstadt, Germany) preconjugated with FFA-free bovine serum albumin (BSA; Sigma-Aldrich; Merck KGAa) at a 1:1 molar ratio. Control cells were grown with the same medium containing FFA-free BSA. If not stated otherwise, cells were incubated for 1 h with 10 µM cathepsin L inhibitor (z-FF-FMK; cat. no. 219421; Calbiochem; EMD Millipore, Billerica, MA, USA) and cathepsin S inhibitor (z-FL-COCHO. H₂O; cat. no. 219393; Calbiochem; EMD Millipore) at 37°C, which was followed by incubation with palmitate or FFA-free BSA for 24 h at 37°C.

**Immunofluorescence staining.** HUVECs were fixed in 4% paraformaldehyde for 20 min and incubated at 37°C in blocking buffer (PBS containing 5% BSA). Cells were incubated in the presence of mouse anti-Cluster of Differentiation (CD) 31 antibody (1:200; cat. no. SC-81158; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 2 h at 37°C and washed three times in PBS. Cells were subsequently incubated with rhodamine-conjugated goat anti-mouse IgG (H+L) secondary antibody (1:1,000; cat. no. 31660; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 1 h at 37°C. Nuclei were stained with DAPI (1:10,000; Invitrogen; Thermo Fisher Scientific, Inc.) and were examined with an Olympus IX70 inverted fluorescence microscope.

**Cell proliferation assay.** The effect of elevated palmitate concentration on HUVEC proliferation was analyzed utilizing Cell Counting kit (CCK)-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer’s protocol. The amount of the formazan dye generated in cells was directly proportional to the number of living cells. Absorbance of the samples was measured at a wavelength of 450 nm.

**Cell apoptosis assay.** HUVECs were grown in M199 medium and pretreated for 1 h at 37°C with indicated protease inhibitors prior to the addition of 0, 0.05, 0.1, 0.2, 0.4 or 0.6 mM palmitate. Following palmitate treatment for 24 h at 37°C, cells were harvested. A total of 1x10⁶ cells were suspended in 200 µl Annexin V binding buffer (BD Biosciences, Franklin Lakes, NJ, USA) and incubated with 2.5 µl annexin V-fluorescein isothiocyanate (FITC) and 2.5 µl propidium iodide (PI; BD Biosciences, Franklin Lakes, NJ, USA) for 15 min at room temperature. The proteins (20 µg total RNA) were reverse transcribed using Trizol® reagent (Sigma-Aldrich; Merck KGAa). cDNA was synthesized from 2 µg total RNA using ReverTra Ace™ qPCR Reverse Transcriptase kit (cat. no. FSQ-101; Toyobo Co., Ltd., Osaka, Japan) according to the manufacturer’s protocol. qPCR was performed using the SYBR-Green Master mix (cat. no. QPK-212; Toyobo Co., Ltd.) in an ABI 7500HT Real-Time PCR machine (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions for PCR were 95°C for 60 sec, followed by 40 cycles at 95°C for 15 sec, 61°C for 15 sec and 72°C for 45 sec. The relative expression level was determined by the 2⁻∆∆Cq method and normalized against GAPDH (15). The primer sequences used were as follows: Forward, 5'-CGAATCTATTAAGATCCGAGTG-3' and reverse, 5'-ATGGTCTAGCAAGCCCCATTG-3' for cathepsin L; forward, 5'-ATTTCCTGTTACGTGAACT-3' and reverse, 5'-TGATGTACTGGAAGCGGTGTG-3' for cathepsin S; forward, 5'-GCCATGTCGATCTGGGTGAA-3' and reverse, 5'-AAGCAGAGAGGGAGAGGGG-3' for cystatin C; and forward, 5'-TGACCACCCACCTGTTAGC-3' and reverse, 5'-GGCATGAGACTGTGGTCAT-3' for GAPDH.

**Western blot analysis.** Cells were lysed in ice-cold radioimmunoprecipitation assay buffer (Sigma-Aldrich; Merck KGAa) supplemented with 1 mM phenylmethylsulfonyl fluoride (Thermo Fisher Scientific, Inc.). The proteins (20 µg per lane) were separated on a 12% SDS-PAGE gel (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and electrotransferred onto a polyvinylidene difluoride membrane. Following transfer, blocking was performed with 5% BSA (Sigma-Aldrich; Merck KGAa) for 1 h at room temperature. Membranes were probed with specific primary antibodies at 4°C overnight and horseradish peroxidase (HRP)-conjugated anti-rabbit/ mouse immunoglobulin secondary antibodies (1:5,000; cat. nos. SC-2004 and SC-2005; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. The primary antibodies used were mouse anti-cathepsin L (1:1,000; cat. no. ab6314; Abcam, Cambridge, UK), rabbit anti-cathepsin S (1:5,000; cat. no. ab50400; Abcam), rabbit anti-cystatin C (1:500; cat.
no. ab33487; Abcam) and mouse anti-tubulin (1:1,000; cat. no. AT819; Beyotime Institute of Biotechnology, Haimen, China). Enhanced chemiluminescence was performed using the Pro-light HRP Chemiluminescence kit according to the instructions of the manufacturer (Tiangen Biotech Co., Ltd., Beijing, China). Membranes were scanned and visualized by an LAS3000 system (LAS3000 mini ImageReader, Fuji Photo Film Co., Ltd., Japan).

Cathepsins L and S activity assay. Cells were lysed and treated with reaction buffer that was included in the kits used for cathepsin L (cat. no. ab65306; Abcam) or cathepsin S (cat. no. ab65307; Abcam), and 10 mM fluorogenic Ac-FR-amino-4-trifluoromethyl coumarin (AFC) substrate, which is the preferred cathepsin L substrate (cat. no. ab65306; Abcam) or 10 mM Ac-VVR-AFC, which is the preferred cathepsin S substrate (cat. no. ab65307; Abcam) according to the manufacturer's protocol. Fluorescence was measured using SpectraMax M5 fluorometer, at an excitation wavelength of 400 nm and an emission wavelength of 505 nm.

Statistical analysis. Data are expressed as the mean ± standard deviation of at least three independent experiments. Multiple group comparisons were performed by one-way analysis of variance followed by the least significant difference post hoc test. All tests analyzed were two-sided. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were conducted using SPSS software version 11.5 (SPSS, Inc., Chicago, IL, USA).

Results

Effect of palmitate and cysteine protease on HUVEC proliferation. HUVECs express the endothelial marker protein CD31 as previously described (16), and as presented in Fig. 1A. To examine the effect of palmitate on HUVEC proliferation, and it was observed that palmitate decreased HUVEC proliferation in a dose-dependent manner (Fig. 1B). High levels of palmitate (0.6 mM) inhibited the proliferation rate significantly by 44±7% (P<0.05 vs. 0 mM), whereas the lowest concentration (0.05 mM) had no significant effect (P=0.09 vs. 0 mM). These results are consistent with a previous report (17).

To determine whether cathepsin is associated with HUVEC proliferation in the presence of a high concentration of FFA, cysteine protease inhibitors were added to the concentrations of palmitate. It was observed that treatment with the cathepsin L inhibitor Z-FF-FMK (Fig. 1C) and the cathepsin S inhibitor Z-FL-COCHO (Fig. 1D) did not result in significant alterations of the growth rate (P>0.05), suggesting palmitate reduced HUVEC proliferation via a cathepsin-independent pathway.

Cysteine protease inhibitors attenuate palmitate-induced HUVEC apoptosis. Palmitate may trigger apoptotic pathways in HUVECs (17); therefore, the present study examined whether cathepsin regulated palmitate-induced HUVEC apoptosis (Fig. 2A). As presented in Fig. 2B, cathepsin L and S inhibitors exhibited the ability to reduce the early apoptosis of HUVECs induced by palmitate by almost 50%, suggesting a key cathepsin-dependent pathway in
Palmitate inhibits cathepsin-mediated cell invasion. Previous reports have demonstrated that cathepsin L is required for endothelial progenitor cell invasion and neovascularization (3,18); however, whether other cathepsins may influence cell invasion and whether the effects of decreased invasion result from increased FFA levels remains to be elucidated. The present study firstly assessed the effect of palmitate on cell invasion ability using a Transwell assay. It was observed...
that 0.4 and 0.6 mM palmitate reduced endothelial cell invasion by 88 and 94%, respectively, compared with untreated cells (Fig. 3), indicating that palmitate inhibits cell invasion in a dose-dependent manner. Furthermore, cathepsin S and L inhibitors significantly reduced the cell migration by almost 2-fold, even in the presence of a high level of palmitate (Fig. 3). These findings indicated that cathepsins contribute to cell migration and invasion and palmitate is a potential factor that may reduce cathepsin-mediated cell invasion.

Palmitate suppresses the activity of cathepsins L and S. To investigate the underlying mechanism of cathepsins L and S reduction in response to high FFA levels, the present study measured the effect of high palmitate levels on the mRNA and protein expression levels, and activities of cathepsin L and S in HUVECs. The protease activity experiment demonstrated that cells incubated in palmitate for 24 h presented a markedly attenuated cathepsin L activity (P<0.05; Fig. 4A) compared with those cells cultured in medium without palmitate. The greatest palmitate level decreased the activity of cathepsin L by almost 3.6 fold (Fig. 4A). In addition, the high palmitate level attenuated cathepsin S activity; however, this alteration was not significant (Fig. 4A). To further analyze the effect of high palmitate levels on protease expression, the present study detected the mRNA expression levels of cathepsin L, S and their natural inhibitor cystatin C, and observed that palmitate increased expression levels in a dose-dependent manner (Fig. 4B and C), suggesting a regulatory interaction between palmitate and cathepsins or their endogenous inhibitor. Consistent with the mRNA expression, cathepsin L protein level was upregulated by high palmitate levels at 0.4 mM but was downregulated by 0.6 mM palmitate (Fig. 4D and E), thus, high palmitate levels (>0.4 mM) may have a role in inhibiting cathepsin L activity. However, the protein expression levels of cathepsin S and cystatin C appeared to vary only slightly with different palmitate concentrations, the differences between the mRNA and protein results may be a result of posttranscriptional modifications.
Discussion

The present study demonstrated that exposure of cultured HUVECs to palmitate led to impairment of cell proliferation and invasion, and increased cell apoptosis, and that the function of palmitate is associated with cathepsin L and S. Further experiments demonstrated that palmitate inhibited the activity of cathepsin L and S in HUVECs.

The effects of FFA on cell proliferation, apoptosis and invasion have previously been investigated; Listenberger et al (10) observed that saturated fatty acids increase nicotinamide adenine dinucleotide phosphate oxidase-generated oxidant stress, nuclear factor-κB activation and ceramide accumulation. The latter, which may be synthesized de novo from saturated fatty acids and the amino acid serine, has been implicated in apoptosis and oxidative stress modulation (19-21). Consistent with these reports, high concentrations of saturated fatty acids may trigger apoptosis and inhibit cell cycle progression in cultured human endothelial cell monolayers (22-24). In addition, trophoblast cells treated with long-chain fatty acids revealed increased lipid droplet deposition, severe mitochondrial damage and significantly decreased invasion (25). The present study demonstrated that the FFA palmitate exhibits similar effects on HUVECs.

Cysteine proteases contribute to angiogenesis under pathophysiological conditions. Cathepsins were originally identified as members of the cysteine protease family localized in lysosomes. However, previous data revealed unexpected roles for cathepsins in pathological conditions including cell survival, metabolic disorder and atherosclerosis-based cardiovascular disease (26-31). However, the definite underlying molecular mechanism remains to be fully elucidated. A variety of cathepsins (B, D, L, S and K) have been demonstrated to cleave the pro-apoptotic B-cell lymphoma-2 (Bcl-2) family member BH3 interacting domain death agonist (Bid) into its potent pro-apoptotic tBid fragment in vitro (32,33). Translocation of these pro-apoptotic fragments to the mitochondrial outer membrane may induce the release of apoptogenic factors including cytochrome c and subsequent activation of downstream caspases. In addition to Bcl-2 family members, caspases may be appropriate candidates as cathepsin substrates (34-39). It was therefore hypothesized that cysteine proteases contribute to the regulation of apoptotic signaling mechanisms. Consistent with this, the present study observed that cathepsin inhibitors protected cells from high FFA level-induced apoptosis. In addition, it has previously been demonstrated that intracellular and extracellular cathepsin S, L and K activities were reduced in non-invasive compared with highly invasive cells (40), and downregulation of cathepsins L and S led to defective endothelial cell invasion and suppression of proliferation (41,42), indicating that cathepsins are important for angiogenesis. Therefore, cathepsins S and L are required for endothelial progenitor cell-induced neovascularization in response to ischemic stress (3,43).

In conclusion, the results of the present study, in conjunction with previous findings, support the anti-angiogenic action of FFA. The results suggested that the cathepsin-dependent effects should be considered when developing novel therapies during human endothelial cell angiogenesis. These findings suggested a novel approach to pharmacological and genetic rescue strategies in FFA-mediated angiogenesis.

Acknowledgements

The present study was funded by the National Natural Science Foundation of China (grant nos. 81300167 and 30873350).

References

1. Binet F and Sapieha P: ER stress and angiogenesis. Cell Metab 22: 556-575, 2015.
2. Pourrajab F, Vakili Zarch A, Hekmatimoghadam S and Zare-Khorzmi MR: MicroRNAs: easy and potent targets in optimizing therapeutic methods in reparative angiogenesis. J Cell Mol Med 19: 2702-2714, 2015.
3. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MB, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, et al: Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 11: 206-213, 2005.
4. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, et al: Deficiency of the cysteine protease cathepsin S impairs microvesSEL growth. Circ Res 92: 493-500, 2003.
5. Conus S and Simon HU: Cathepsins: Key modulators of cell death and inflammatory responses. Biochem Pharmacol 76: 1374-1382, 2008.
6. Droga-Mazoeck G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, Salvesen GS, Stoka V, Turk V and Turk B: Cysteine cathepsins trigger caspase-dependent cell death during cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem 283: 19140-19150, 2008.
7. Zheng X, Chu F, Mirkin BL, Sudha T, Mousa SA and Rebbaa A: Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy. Biochim Biophys Acta 1783: 2294-2300, 2008.
8. Shulman GL: Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176, 2000.
9. Boden G and Shulman GI: Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32 (Suppl 3): S14-S23, 2002.
10. Listenberger LL, Ory DS and Schaffer JE: Palmitate-induced apoptosis can occur through a ceramic-independent pathway. J Biol Chem 276: 14890-14895, 2001.
11. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS and Schaffer JE: Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 100: 3077-3082, 2003.
12. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M and Honjo T: Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem 272: 3324-3329, 1997.
13. Cnop M, Hanaert JC, Hoorens A, Eizirik DL and Pipeleers DG: Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 50: 1771-1777, 2001.
14. Ostrander DB, Sparagna GC, Amosco AA, McMillon JB and Dowhan W: Decreased cardiopin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis. J Biol Chem 276: 38061-38067, 2001.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
16. Pintar E, Mahooti S, Wang Y, Imhof BA and Madri JA: Hyperglycemia-induced vasculopathy in the murine vitelline vasculature: Correlation with PECAM-1/CD31 tyrosine phosphorylation state. Am J Pathol 154: 1367-1379, 1999.
17. Ciapaite J, van Bezu J, van Eijkenhorst G, Bakker SJ, Teerlink T, Diamant M, Heine RJ, Krab K, Westerhoff HV and Schalkwijk CG: Palmitate and oleate have distinct effects on the inflammatory phenotype of human endothelial cells. Biochim Biophys Acta 1771: 147-154, 2007.
18. Urbich C, Dernbach E, Rössig L, Zeiher AM and Dimmeler S: High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells. J Mol Cell Cardiol 45: 429-436, 2008.
and

3578-3587 multiple papain-like lysosomal cathepsins in HeLa cells triggers apoptosis mediated by cleavage of Bid by Salvesen GS and Turk B: J Clin Invest 107: 813-822, 2001.

32. Vafaiadou K, Weech M, Sharma V, Yaqoob P, Todd S, Williams CM, Jackson KG and Lovegrove JA: A review of the evidence for the effects of total dietary fat, saturated, monounsaturated and n-6 polyunsaturated fats on vascular function, endothelial progenitor cells and microparticles. Br J Nutr 107: 303-324, 2012.

33. Heinrich M, Neumeyer J, Jakob M, Hallas C, Tchikov V, Winotto-Morbach S, Wickel M, Schneider-Bracht W, Trauzold A, Hethke A and Schütze S: Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ 11: 550-563, 2004.

34. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, Bredesen D, Freeze H, Abrahamsson M, et al: Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem 276: 3149-3157, 2001.

35. Guicciardi ME, Leist M and Gores GJ: Lysosomes in cell death. Oncogene 23: 2881-2890, 2004.

36. Schotte P, Van Criekinge W, Van de Craen M, Van Loo G, Desmedt M, Grooten J, Cornellissen M, De Ridder L, Vandekerkhove J, Fiers W, et al: Cathepsin B-mediated activation of the proinflammatory caspase-11. Biochem Biophys Res Commun 251: 379-387, 1998.

37. Vancompernolle K, Van Herreweghe F, Pynaert G, Van de Craen M, De Vos K, Totty N, Sterling A, Fiers W, Vandenaabbe P and Groten J: Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett 438: 150-158, 1998.

38. Ishisaka R, Utsumi T, Kanno T, Arita K, Katunuma N, Akita J and Utsumi K: Participation of a cathepsin L-type protease in the activation of caspase-3. Cell Struct Funct 24: 465-470, 1999.

39. Ishisaka R, Kanno T, Akita J, Yoshitoka T, Utsumi K and Utsumi T: Activation of caspase-3 by lysosomal cysteine proteases and its role in 2,2′-azobis-(2-amidinopropane) dihydrochloride (AAPH)-induced apoptosis in HL-60 cells. J Biochem 129: 35-41, 2001.

40. Tsai JY, Lee MJ, Dah-Tsyr Chang M and Huang H: The effect of catalase on migration and invasion of lung cancer cells by regulating the activities of cathepsin S, L, and K. Exp Cell Res 323: 28-40, 2014.

41. Zhang Q, Han M, Wang W, Song Y, Chen G, Wang Z and Liang Z: Downregulation of cathepsin L suppresses cancer invasion and migration by inhibiting transforming growth factor-β-mediated epithelial-mesenchymal transition. Oncol Rep 33: 1851-1859, 2015.

42. Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA and Scott CJ: Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res 15: 6042-6051, 2009.

43. Li X, Cheng XW, Hu L, Wu H, Guo-Ping, Hao CN, Jiang H, Zhu E, Huang Z, Inoue A, et al: Cathepsin S activity controls ischemia-induced neovascularization in mice. Int J Cardiol 183: 198-208, 2015.